Evidence map›Paper›PMID 40027169›Full record

ArticleFrontiers in neurology2025

Pyrotinib-assisted whole brain radiotherapy alleviates HER2-positive advanced breast cancer and brain metastases: a prospective study in patients.

Fulin Zhou, Cui Zhang, Mingyuan He, Yu Ren, Hongshuang Yue, Zhihua Tan, Shaolin Zhang, Yong Li, Shu Liu

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fulin Zhou *Department of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Cui Zhang *Zunyi Medical University, Zunyi, China.
Mingyuan He *Department of Oncology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yu RenDepartment of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Hongshuang YueDepartment of Breast Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Zhihua TanDepartment of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Shaolin ZhangDepartment of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Yong LiDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
Shu LiuDepartment of Clinical Medicine, Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The whole-brain radiotherapy (WRBT)-based therapeutic efficacy is often limited against human epidermal growth factor receptor 2 (HER2+)-positive advanced breast cancer (BC) and brain metastases (BM), requiring more effective treatment options. This prospective study evaluates the effectiveness and safety of combining WBRT with pyrotinib in patients with HER2+ advanced BC and BM. Methods: The enrolled patients ( Results: In the WBRT-p group ( Conclusion: WBRT combined with pyrotinib exhibited exceptional tolerability, showing long iPFS in patients with HER2+ advanced BC and BM.

Indexed as

brain metastasisbreast cancerhuman epidermal growth factor receptor-2pyrotinibwhole brain radiotherapy

Identifiers

PMID40027169
PMCPMC11868727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.